NORCET
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NORCET (NORCET).
Combination analgesic: hydrocodone acts as a μ-opioid receptor agonist; acetaminophen inhibits cyclooxygenase (COX) and modulates endocannabinoid system, exerting central analgesic and antipyretic effects.
| Metabolism | Hydrocodone: extensively metabolized via CYP3A4 and CYP2D6 to hydromorphone and norhydrocodone. Acetaminophen: primarily metabolized by conjugation (glucuronidation and sulfation); minor oxidation via CYP2E1, CYP1A2, and CYP3A4 to toxic N-acetyl-p-benzoquinone imine (NAPQI). |
| Excretion | Renal: ~60% unchanged; hepatic metabolism to inactive glucuronide conjugates; biliary/fecal: <5% |
| Half-life | 2-4 hours (terminal); prolonged in hepatic impairment (up to 8-10 hours) and elderly |
| Protein binding | 95% bound; primarily to albumin and alpha1-acid glycoprotein |
| Volume of Distribution | 2-3 L/kg; indicates extensive tissue distribution |
| Bioavailability | Oral: 80-100% (extensive first-pass metabolism reduces to ~60% active drug); IM: 100% |
| Onset of Action | Oral: 30-60 minutes; IV: 5-10 minutes; IM: 15-30 minutes |
| Duration of Action | 4-6 hours (analgesic); clinical effect may last up to 8 hours due to active metabolite (nortriptyline) |
1-2 tablets (containing paracetamol 325 mg and tramadol 37.5 mg) orally every 4-6 hours as needed for pain, maximum 8 tablets per day.
| Dosage form | TABLET |
| Renal impairment | For CrCl 30-50 mL/min: extend interval to every 6-8 hours. For CrCl <30 mL/min: not recommended. Avoid in severe renal impairment (CrCl <15 mL/min). |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 1 tablet every 8-12 hours. Child-Pugh C: contraindicated. |
| Pediatric use | Not recommended in children <12 years due to tramadol risk of respiratory depression. For adolescents 12-18 years: same adult dosing based on pain severity, with maximum 8 tablets/day. |
| Geriatric use | Start at lowest dose (1 tablet every 6-8 hours), monitor renal function, avoid in patients with respiratory compromise. Maximum 6 tablets/day for those >75 years. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NORCET (NORCET).
| Breastfeeding | Small amounts of ethinyl estradiol and norethindrone are excreted into breast milk. M/P ratio not well defined. Use may reduce milk production and affect infant growth. Generally, combined hormonal contraceptives are not recommended during breastfeeding, especially in the early postpartum period. Progestin-only alternatives are preferred. |
| Teratogenic Risk | NORCET (norethindrone acetate and ethinyl estradiol) is contraindicated in pregnancy. First trimester: Use is associated with a slightly increased risk of cardiovascular and limb defects. Second and third trimesters: Use may cause feminization of male fetuses, urogenital sinus abnormalities in females, and cardiovascular or genital anomalies. Overall, absolute risk is low, but use is not recommended. |
■ FDA Black Box Warning
Addiction, abuse, and misuse: can lead to addiction and fatal overdose. Life-threatening respiratory depression: risk highest at initiation and with dose increases. Accidental ingestion of acetaminophen can cause fatal hepatotoxicity. Neonatal opioid withdrawal syndrome: prolonged use during pregnancy can result in withdrawal in newborns. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death. CYP3A4 inhibitors or discontinuation of CYP3A4 inducers can cause fatal respiratory depression.
| Serious Effects |
Hypersensitivity to hydrocodone, acetaminophen, or any component; significant respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction (including paralytic ileus); severe hepatic impairment; concurrent use of MAOIs or within 14 days of discontinuation.
| Precautions | Risk of respiratory depression, especially in elderly or debilitated; increased risk of serotonin syndrome with concomitant serotonergic drugs; adrenal insufficiency; severe hypotension; hepatotoxicity due to acetaminophen; risk of overdose with concurrent acetaminophen-containing products; opioid-induced hyperalgesia; seizures in patients with epilepsy; impaired driving or operating machinery; use in patients with head injury or increased intracranial pressure. |
Loading safety data…
| Fetal Monitoring | If inadvertently used during pregnancy, monitor fetal anatomy via ultrasound for potential anomalies. No specific monitoring mandated if discontinued upon pregnancy diagnosis. Routine prenatal care is sufficient. |
| Fertility Effects | No permanent adverse effects on fertility. May transiently delay return to ovulation after discontinuation; normal fertility typically resumes within 1-3 cycles. |